# CJC-1295 Dosage: The Doses Used in Published Research > CJC-1295 human PK studies used single subcutaneous doses of 30, 60 or 90 ug/kg; a GHRH-knockout mouse study used 2 ug. The research-dose record, with no human protocol. Single subcutaneous 30, 60 or 90 ug/kg in human pharmacokinetic studies; 2 ug per dose in the knockout-mouse growth work. What was administered, to which species, by which route — and where the controlled data stop. ## Doses Used in Published CJC-1295 Research The CJC-1295 dosage figures worth trusting come from controlled studies, and there are only a handful. Human pharmacokinetic work used single subcutaneous doses of 30, 60 or 90 micrograms per kilogram: the 30 and 60 ug/kg arms established the dose-dependent multi-day GH/IGF-1 kinetics and the 5.8-to-8.1-day half-life [1], and the 60 and 90 ug/kg arms established the preserved-pulsatility result with basal GH up about 7.5-fold and IGF-1 up about 45% at one week [3]. In GHRH-knockout mice, the growth study used 2 micrograms per dose, comparing 24-, 48- and 72-hour intervals [4]. What makes those figures coherent is that the dose response and the duration were measured together. The human studies expressed dose per kilogram of body weight, not as a fixed quantity, and read the output as plasma GH and IGF-1 over many days — so a "dose" in this literature is inseparable from the multi-day exposure window the DAC half-life creates [1]. The knockout-mouse work added the scheduling dimension: 2 ug once every 24 hours fully normalized growth, while the same dose given every 48 or 72 hours was progressively less effective, showing that the long-acting analog's value is a once-daily-or-better cadence rather than a single large hit [4]. Those are the numbers with a study behind them. Community and clinic protocols circulating for the no-DAC "Modified GRF 1-29" form and for CJC-1295/ipamorelin commonly cite fixed doses in the 100-to-300-microgram range, but these are not derived from controlled human trials. They are also not directly comparable to the study doses, which were weight-scaled rather than fixed. This site reports what was administered in research; it does not convert any of it into a human protocol and recommends no dose for any person. ### How much CJC-1295 was used in studies? Human PK studies used single subcutaneous doses of 30, 60 or 90 ug/kg; community protocols (100-300 ug fixed) are not derived from controlled human trials [1][3]. No human dosing is recommended here. The 2 ug GHRH-knockout-mouse dose belongs to a growth-normalization study, not a human-equivalent figure [4]. ## Half-life, routes and handling Pharmacokinetics is where the DAC engineering shows up. The CJC-1295 DAC half-life was estimated at 5.8 to 8.1 days in healthy adults, and IGF-1 elevation persisted up to 28 days after multiple doses — which is why a single DAC injection moves the axis for over a week [1]. The short-acting no-DAC Modified GRF (1-29) form behaves very differently, clearing in a minutes-to-hours window that reflects native GHRH(1-29) kinetics with the protease-resistant substitutions but without the albumin bond. The two forms are covered side by side on the [CJC-1295 half-life](/dac-vs-no-dac) page. ### Routes studied Subcutaneous injection is the primary route in the published research; early GRF(1-29) pharmacokinetic work also used intravenous administration [1][2]. This reflects how studies administered the peptide, not a human-use recommendation. ### Where to inject CJC-1295? Subcutaneous injection is the route used across the controlled studies. The published work does not prescribe an injection site for any person; it documents that the molecule was delivered subcutaneously in the trials that characterized its kinetics [1][3]. This describes study methodology, not a how-to. ### Reconstitution and handling in research In research handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; oral bioavailability is negligible because it is a peptide [1]. The four substitutions confer protease resistance and the DAC conjugation confers the multi-day duration. This describes laboratory handling, not human-use instructions. A note on handling identity: the molecule logged in this research carries CAS 863288-34-0 for the DAC variant, with a molar mass near 3,367.9 Da before albumin conjugation, though chemical registries disagree on the exact molecular formula — a discrepancy worth flagging rather than smoothing over, since a reader checking a source against a supplier listing may encounter both [2]. The behavior that matters for the dose-response record is the one the human studies measured: a single weight-scaled subcutaneous dose producing a multi-day GH and IGF-1 elevation, reproducible across the Frohman-lab pharmacokinetic work [1][3]. Everything past that point — fixed-microgram protocols, multi-week schedules, combination regimens — sits outside the controlled human record, which is exactly why this page reports doses and stops short of recommending any. ## DAC-form doses and the limits of the human record ### CJC-1295 DAC doses in the literature Healthy-adult pharmacokinetic studies of the DAC form used 30 or 60 ug/kg subcutaneously; the multi-day half-life is why a single dose elevates GH and IGF-1 for days [1]. These are research doses, not a human protocol. The DAC variant's covalent albumin bond is what separates it from the short-acting no-DAC form on every dose-response axis [2]. The human dataset is small and short-term. The phase 1/early human pharmacokinetic studies in healthy volunteers established the GH/IGF-1 kinetics; a ConjuChem phase 2 trial in HIV-associated visceral obesity (NCT00267527) was discontinued, and the DAC development program did not advance. There are no large efficacy or long-term safety trials in healthy adults, and CJC-1295 is not approved for human use anywhere [1]. A reader looking for a validated dosing schedule will not find one in the peer-reviewed record — only the research doses above and the gap where controlled long-term data would be. The [reported and theoretical concerns](/faq) that accompany sustained GH/IGF-1 elevation are catalogued on the FAQ. --- An emerald-on-black console reading of the CJC-1295 record — the four substitutions, the DAC albumin handle, and the multi-day-versus-short-acting half-life each logged to its study and split by form, with no clinic behind the panel and nothing here dispensed or sold.